Quarter
Charts

Definium Therapeutics, Inc.

DFTX

CIK 0001813814 · Quarterly mode · latest period FY2023 (Q4) (ending 2023-12-31) · sourced from SEC EDGAR

At a glance · FY2023 (Q4)

Revenue
$905K
↓-14.0% -$147Kvs FY2022 (Q4)
Gross Profit
$905K
↓-14.0% -$147Kvs FY2022 (Q4)

Quality Score

Quality score

6-dimension fundamental snapshot · latest annual filed values · S&P 500 calibration

Weak
32/100
  • Profitability
    0ROIC -41.3% (10% = solid, 20%+ = moat)
  • Liquidity
    100Current Ratio 6.29 (above 1.5 = solid)
  • Leverage
    94D/E 0.12 (under 0.5 = conservative)
  • Efficiency
    0Asset Turnover 0.03x (1.0+ = capital-efficient)
  • Growth
    0Revenue YoY -14.0% (10% = solid, 25%+ = elite)
  • Margin Trend
    0Insufficient data

Calibrated to S&P 500 medians. Each sub-score is computed from a single CFA-grade ratio (Profitability = ROIC, Liquidity = Current Ratio, Leverage = D/E, Efficiency = Asset Turnover, Growth = Revenue YoY, Margin Trend = 4Q operating-margin avg vs prior 4Q). Overall = simple mean.

Balance sheet · 2025-12-31

latest filed snapshot
Total assets
$440M
everything owned
Total liabilities
$108M
everything owed
Stockholders' equity
$332M
shareholder claim
Net debt
$-217M
Net cash position ($217M)

Recent performance · 20 quarters

Revenue↓-14.0% -$147K
$905K
Net Income↓-391.6% -$54M
$-67M
Free Cash Flow↓-77.2% -$13M
$-29M
Operating Margin↑+2858.9pts
-1858.6%

Drill down

DFTX Sankey

See Definium Therapeutics, Inc.'s revenue flow into every line item of the income statement and balance sheet — every dollar accounted for, with prior-period comparison.

Open Sankey

DFTX Charts

20 quarters of historical line items — Income, Cash Flow, Balance Sheet, plus margins. Click any chart for the trend dialog.

Open Charts

DFTX Key Metrics

EPS, BVPS, FCF/Share, ROE, ROA, ROIC, D/E, Current Ratio, Quick Ratio, Asset Turnover — 10 CFA-grade fundamentals derived from EDGAR data.

Open Key Metrics